SCHEMBL6492800

SCHEMBL6492800

CCOC(=O)N(C)c1ccc(C)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.50
RAB9A P51151 3/20 0.47
TSHR P16473 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
HPGD P15428 4/20 0.43
ALDH1A1 P00352 2/20 0.43
KMT2A Q03164 1/20 0.43
CYP2C19 P33261 2/20 0.43
CHRNB2 P17787 2/20 0.43
CHRNB4 P30926 2/20 0.43
CHRNA3 P32297 2/20 0.43
CHRNA4 P43681 2/20 0.43
CYP3A4 P08684 1/20 0.43
GPBAR1 Q8TDU6 1/20 0.43
NPC1 O15118 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
S1PR1 P21453 1/20 0.41
MAPT P10636 1/20 0.41
DHODH Q02127 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL996210 0.83 LMNA (0.51) LMNARAB9ATSHRSMN1; SMN2HPGD
SCHEMBL6490972 0.82 LMNA (0.46) LMNATSHRSMN1; SMN2HPGDALDH1A1
SCHEMBL8258018 0.81 LMNA (0.54) LMNARAB9ATSHRSMN1; SMN2KMT2A
SCHEMBL27556216 0.80 LMNA (0.44) LMNATSHRSMN1; SMN2HPGDALDH1A1
SCHEMBL9357885 0.80 CHRNB2 (0.61) LMNARAB9ATSHRSMN1; SMN2ALDH1A1
SCHEMBL6494266 0.80 CHRNA1 (0.43) RAB9ASMN1; SMN2HPGDKMT2ACYP2C19
SCHEMBL11810258 0.79 LMNA (0.54) LMNATSHRSMN1; SMN2HPGDALDH1A1
SCHEMBL11006800 0.78 SMN1; SMN2 (0.53) RAB9ASMN1; SMN2ALDH1A1CYP2C19CHRNB2
SCHEMBL10885835 0.78 S100B (0.51) LMNATSHRSMN1; SMN2ALDH1A1CHRNB2
SCHEMBL27737822 0.78 HTR3E (0.51) LMNARAB9ATSHRSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A LMNA 2742/4885RAB9A 2833/4885TSHR 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.